JPH04346911A - Cosmetic - Google Patents
CosmeticInfo
- Publication number
- JPH04346911A JPH04346911A JP3271691A JP27169191A JPH04346911A JP H04346911 A JPH04346911 A JP H04346911A JP 3271691 A JP3271691 A JP 3271691A JP 27169191 A JP27169191 A JP 27169191A JP H04346911 A JPH04346911 A JP H04346911A
- Authority
- JP
- Japan
- Prior art keywords
- water
- cosmetic
- extract
- soluble extract
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、新規な化粧料に関する
。さらに詳しくは、ゆきのした科の植物の水溶性抽出物
を有効成分として含有する美白作用及び抗炎症作用を持
つ化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a new cosmetic composition. More specifically, the present invention relates to a cosmetic containing a water-soluble extract of a plant of the Yukinoshita family as an active ingredient and having whitening and anti-inflammatory effects.
【0002】0002
【従来の技術】皮膚のしみ、そばかすなどの発生機構に
ついては不明な点もあるが、一般には、ホルモンの異常
や日光からの紫外線の刺激が原因となってメラニン色素
が形成され、これが皮膚内に異常沈着するものと考えら
れている。この様な、しみやそばかすの治療には、皮膚
内に存在するチロジナーゼ活性を阻害してメラニン生成
を抑制する物質、例えば、ビタミンCを大量に投与する
方法、グルタチオンを軟膏、クリーム、ローションなど
の形態にして局所に塗布する方法などがとられている。
また、欧米ではハイドロキノン製剤が医薬品として用い
られている。[Prior Art] Although the mechanism by which skin spots and freckles occur is unclear, in general, melanin pigments are formed due to hormonal abnormalities or stimulation of ultraviolet rays from sunlight, and this is caused within the skin. It is thought that it is abnormally deposited in To treat such age spots and freckles, substances that inhibit tyrosinase activity in the skin and suppress melanin production, such as large doses of vitamin C, and glutathione in ointments, creams, and lotions, etc. Methods such as making it into a form and applying it locally are used. Additionally, hydroquinone preparations are used as pharmaceuticals in Europe and America.
【0003】一方、さまざまな皮膚刺激、例えば、紫外
線の作用により皮膚は炎症を起こすが、これらの炎症を
抑制するものが、抗炎症剤であり、化粧料用成分として
は、アロエ、ヘチマ等の植物抽出物、グリチルリチン、
亜鉛華等が用いられている。[0003] On the other hand, the skin is inflamed due to various skin irritations, such as the action of ultraviolet rays, and anti-inflammatory agents are used to suppress these inflammations. plant extract, glycyrrhizin,
Zinc white etc. are used.
【0004】また、皮膚の角質層より水分が減少すると
肌荒れなどの原因となる。角質層に適当な水分含量を与
えるため、保湿剤として、グリセリン、1,3−ブチレ
ングリコール、プロピレングリコール、ヒアルロン酸等
が用いられている。[0004] Furthermore, a decrease in water content from the stratum corneum of the skin causes rough skin. Glycerin, 1,3-butylene glycol, propylene glycol, hyaluronic acid, and the like are used as humectants to provide the stratum corneum with an appropriate moisture content.
【0005】[0005]
【発明が解決しようとする課題】ビタミンC類は、熱、
光に対し経時的安定性が悪く、特に、水分を含む系で変
色、変臭の原因となる。一方、ハイドロキノン系は皮膚
刺激、アレルギー性等の安全性に問題があるため、使用
が制限されている。また、空気酸化されやすいため安定
性の面においても問題がある。グルタチオン、システイ
ン等のチオール系化合物は異臭が強い上、酸化されやす
く効果も緩慢である。また、2−メルカプトエチルアミ
ン塩、N−(2−メルカプトエチル)ジメチルアミン塩
等は、黒色モルモットの皮膚を脱色することが知られて
いるが、脱色後に白班が生じやすいので、一般には使用
されていない。[Problem to be solved by the invention] Vitamin C
It has poor stability against light over time and causes discoloration and odor, especially in systems containing water. On the other hand, the use of hydroquinone is restricted due to safety issues such as skin irritation and allergy. In addition, it is susceptible to air oxidation, which poses a problem in terms of stability. Thiol compounds such as glutathione and cysteine have a strong off-flavor, are easily oxidized, and have slow effects. Furthermore, 2-mercaptoethylamine salt, N-(2-mercaptoethyl)dimethylamine salt, etc. are known to bleach the skin of black guinea pigs, but they are not commonly used because they tend to cause white spots after bleaching. do not have.
【0006】一方、美白作用及び抗炎症作用を有する成
分は前記のごとくさまざまなものがあるが、それらの効
果を合わせもつ化粧料を製造するためには、それらの複
数の成分をそれぞれ添加するしかなく、製品の安定性等
留意しなければならない点が多い。On the other hand, as mentioned above, there are various ingredients that have whitening and anti-inflammatory effects, but in order to produce cosmetics that have both of these effects, it is necessary to add each of these ingredients. However, there are many points that must be kept in mind, such as product stability.
【0007】本発明者らは、かかる状況を鑑み、鋭意研
究を重ねた結果、ゆきのした科の植物の水溶性抽出物を
有効成分として含有する化粧料が、良好な美白作用及び
抗炎症作用を有することを見いだし、本発明を完成する
に至った。In view of this situation, the present inventors have conducted intensive research and found that a cosmetic containing a water-soluble extract of a plant in the Yukinoshita family as an active ingredient has good whitening and anti-inflammatory effects. The present invention has been completed based on this discovery.
【0008】[0008]
【課題を解決するための手段】本発明は、ゆきのした科
の植物の水溶性抽出物を有効成分として含有する化粧料
である。[Means for Solving the Problems] The present invention is a cosmetic containing a water-soluble extract of a plant of the Yukinoshita family as an active ingredient.
【0009】本発明で使用するゆきのした科の植物とは
、ユキノシタ(Saxifragastolonife
ra Meerb.)、ヤグルマソウ(Rodger
sia podopyhlla A.Gray),
ハナネコノメ(Chysosplenium sta
mineum Franch.)、ズダヤクシユ(T
iarella polyphylla Don)
、アジサイ(Hydrangeamacrophyll
a Seringe var.otaksa M
akino)、ウメウツギ(Deutzia uni
flora Shirai)等の植物である。(原色
牧野植物大図鑑、牧野富太郎著、北隆館、)[0009] The plant of the Yukinoshita family used in the present invention is Saxifragastolonife.
ra Meerb. ), Cornflower (Rodger
sia podopyhlla A. Gray),
Chysosplenium sta
mineum Franch. ), Zudayakushiyu (T
iarella polyphylla Don)
, Hydrangea (Hydrangea macrophyll)
a Seringe var. otaksa M
akino), Deutzia uni (Deutzia uni)
flora Shirai) and other plants. (Illustrated encyclopedia of primary color Makino plants, written by Tomitaro Makino, Hokuryukan)
【0010】本発明で使用する水溶性溶媒とは水もしく
は水に可溶な溶媒で、例えば、水、アルコール類(メタ
ノール、エタノール、1,3−ブチレングリコール、プ
ロピレングリコール等)、アセトンなどのが挙げられる
。また、本発明の植物の抽出は、これらの水溶性溶媒の
1種または2種以上の混合溶媒を用いて抽出したもので
あっても良い。また、加熱抽出したものであっても良い
し、常温抽出したものであっても良い。必要に応じて、
濃縮あるいは希釈して化粧品原料として用いることが出
来る。The water-soluble solvent used in the present invention is water or a solvent soluble in water, such as water, alcohols (methanol, ethanol, 1,3-butylene glycol, propylene glycol, etc.), acetone, etc. Can be mentioned. Furthermore, the plant of the present invention may be extracted using one or a mixed solvent of two or more of these water-soluble solvents. Further, it may be extracted by heating or extracted at room temperature. as needed,
It can be concentrated or diluted and used as a cosmetic raw material.
【0011】本発明の化粧料には、ゆきのした科の植物
の水溶性抽出物の効果を損なわない範囲内で、油脂類、
ロウ類、炭化水素類、脂肪酸類、アルコール類、エステ
ル類、金属石鹸、界面活性剤などを原料として配合する
ことができる。The cosmetic of the present invention may contain oils and fats within the range that does not impair the effects of the water-soluble extract of plants of the Yukinoshita family.
Waxes, hydrocarbons, fatty acids, alcohols, esters, metal soaps, surfactants, and the like can be blended as raw materials.
【0012】これらの基材を原料として製造される化粧
料としては、例えば、化粧水、クリーム、乳液、シャン
プー、ファンデーション、リップクリーム、口紅などが
挙げられる。Cosmetics produced using these base materials as raw materials include, for example, lotions, creams, milky lotions, shampoos, foundations, lip balms, and lipsticks.
【0013】本発明の化粧料に用いるゆきのした科の植
物の水溶性抽出物の使用量は、溶媒を留去して得られた
固形分として、化粧料全体に対して0.01から10重
量%、好ましくは、0.1から5.0重量%配合するの
が適当である。0.01重量%未満では十分な効果が望
めず、10重量%を越えて配合しても効果の増強がなく
不経済である。[0013] The amount of the water-soluble extract of the Yukinoshita family plant used in the cosmetic of the present invention is 0.01 to 10% by weight based on the entire cosmetic as a solid content obtained by distilling off the solvent. %, preferably 0.1 to 5.0% by weight. If it is less than 0.01% by weight, no sufficient effect can be expected, and if it exceeds 10% by weight, the effect will not be enhanced and it is uneconomical.
【0014】また、添加の方法については、予め加えて
おいても、製造途中で添加しても良く、作業性を考えて
、適宜選択すれば良い。[0014] Furthermore, the method of addition may be either added in advance or added during production, and may be selected as appropriate in consideration of workability.
【0015】[0015]
【実施例】以下に実施例を挙げて本発明を更に具体的に
説明するが、本発明は何らこれらに限定されるものでは
ない。なお、実施例に示す部とは重量部を、%とは重量
%を示す。[Examples] The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited to these in any way. In addition, the part shown in an Example shows a weight part, and % shows a weight%.
【0016】実施例−1
乾燥したユキノシタ100gを細断し、水1000ml
で2時間ずつ2回加熱抽出し、さらに真空凍結乾燥によ
り濃縮することにより抽出物20g(99%以上の固形
物を含む)を得た。Example-1 100g of dried saxifrage was shredded and 1000ml of water was added.
The extract was heated and extracted twice for 2 hours each time, and further concentrated by vacuum freeze-drying to obtain 20 g of an extract (containing 99% or more solids).
【0017】実施例−2
乾燥したアジサイ100gを粉砕し、水−エタノール混
液(1:1)1000mlで5時間加熱抽出して、さら
に濃縮することにより抽出物30g(50%の固形物を
含む)を得た。Example-2 100 g of dried hydrangea was ground, heated and extracted with 1000 ml of a water-ethanol mixture (1:1) for 5 hours, and further concentrated to yield 30 g of extract (containing 50% solids). I got it.
【0018】実施例−3
乾燥したユキンノシタ100gを粉砕し、エタノール1
000mlを加え、常温で1カ月放置する。さらに濃縮
することにより抽出物23g(99%以上の固形物を含
む)を得た。Example 3 100 g of dried Saxifrage was ground and mixed with 1 ethanol of ethanol.
Add 000ml and leave it at room temperature for one month. Further concentration yielded 23 g of extract (containing more than 99% solids).
【0019】実施例−4
乾燥したヤグルマソウ100gを粉砕し、プロパノール
1000mlで2時間ずつ2回加熱抽出し、さらに濃縮
することにより抽出物25g(70%の固形物を含む)
を得た。Example 4 100 g of dried cornflower was crushed, heated and extracted twice with 1000 ml of propanol for 2 hours each time, and further concentrated to obtain 25 g of extract (containing 70% solids).
I got it.
【0020】実施例−5 化粧水
(1)ヤグルマソウの熱水抽出物
(固形物として99%)
5.0部(2)グリセリ
ン
2.0(3)エチルアルコール
7.0(4)パラオキシ安息香酸メチル
0.05(5)ポリオ
キオシエチレン
(20)ラウリルエーテル
0.5(6)クエン酸
0.01(7)クエン酸ナトリウム
0.1(8)香料
0
.1(9)精製水にて全量を100とする
成分(2)〜(4)、(8)を混合して溶解する。別に
成分(1)、(5)〜(7)、(9)を混合して溶解す
る。ついで両者を混合し、テトロン製布(300メッシ
ュ)により瀘過し、製品とする。Example 5 Lotion (1) Hot water extract of cornflower (99% as solid)
5.0 parts (2) Glycerin
2.0(3) Ethyl alcohol
7.0(4) Methyl paraoxybenzoate
0.05(5) Polyoxyoxyethylene (20) Lauryl ether
0.5 (6) citric acid
0.01(7) Sodium citrate
0.1 (8) Fragrance
0
.. 1(9) Mix and dissolve components (2) to (4) and (8) to make the total amount 100% with purified water. Separately, components (1), (5) to (7), and (9) are mixed and dissolved. Then, both are mixed and filtered through Tetron cloth (300 mesh) to obtain a product.
【0021】実施例−6 クリーム
(1)ユキノシタの熱水抽出物
(固形物として99%)
2.0部(2)スクワラン
5.5(3)オリーブ油
3
.0(4)ステアリン酸
2.0(5)ミツロ
ウ
2.0(6)ミリスチン酸オクチ
ルドデシル 3.5(7)
ポリオキシエチレン(20)
セチルエーテル
3.0(8)ベヘニ
ルアルコール
1.5(9)グリセリンモノステアレート
2.5(10)1,3
−ブチレングリコール 8
.5(11)パラオキシ安息香酸メチル
0.2(12)パラオキシ安息香酸
エチル 0.05(1
3)香料
0.1(14)精製水
にて全量を100とする成分(2)〜(9)を加熱溶解
して混合し、70℃に保ち油相とする。成分(1)、(
10)〜(12)を成分(14)に加熱溶解して混合し
、75℃に保ち水相とする。油相に水相を加えて乳化し
、成分(13)を加えてかき混ぜながら、30℃まで冷
却して製品とする。Example 6 Cream (1) Hot water extract of Saxifrage (99% as solid)
Part 2.0 (2) Squalane
5.5(3) Olive oil
3
.. 0(4) Stearic acid
2.0 (5) Beeswax
2.0(6) Octyldodecyl myristate 3.5(7)
Polyoxyethylene (20) Cetyl ether
3.0(8) Behenyl alcohol
1.5(9) Glycerin monostearate
2.5(10)1,3
-Butylene glycol 8
.. 5(11) Methyl paraoxybenzoate
0.2(12) Ethyl paraoxybenzoate 0.05(1
3) Fragrance
0.1 (14) Components (2) to (9) made to a total volume of 100 with purified water are dissolved and mixed by heating, and the mixture is kept at 70°C to form an oil phase. Ingredients (1), (
10) to (12) are heated and dissolved in component (14), mixed, and kept at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase to emulsify, add component (13), and cool to 30°C while stirring to obtain a product.
【0022】実施例−7 乳液
(1)ユキノシタのエタノール抽出物
(固形分として99%)
1.0部(2)スクワラ
ン
5.0(3)オリーブ油
5.0(4)ホホバ油
5.0(5)セチルアルコール
1.5(6)グ
リセリンモノステアレート
2.0(7)ポリオキシエチレン(20)
セチルエーテル
3.0(8)ポ
リオキシエチレン(20)
ソルビタンモノオレエート
2.0(9)ジプロピレン
グリコール
1.0(10)グリセリン
2.0(
11)香料
0.1(12)
パラオキシ安息香酸メチル
0.2(13)精製水にて全量を100とす
る成分(2)〜(8)を加熱溶解して混合し、70℃に
保ち油相とする。成分(1)、(9)、(10)、(1
2)を成分(13)に加熱溶解して混合し、75℃に保
ち水相とする。油相に水相を加えて乳化分散し、成分(
11)を加えてかき混ぜながら、30℃まで冷却し製品
とする。Example 7 Emulsion (1) Ethanol extract of Saxifrage (99% as solid content)
1.0 part (2) Squalane
5.0 (3) Olive oil
5.0 (4) Jojoba oil
5.0(5) Cetyl alcohol
1.5(6) Glycerin monostearate
2.0 (7) Polyoxyethylene (20) Cetyl ether
3.0 (8) Polyoxyethylene (20) Sorbitan Monooleate
2.0(9) Dipropylene glycol
1.0 (10) Glycerin
2.0(
11) Fragrance
0.1 (12)
Methyl paraoxybenzoate
0.2 (13) Make the total amount 100 with purified water. Components (2) to (8) are dissolved and mixed by heating, and the mixture is kept at 70°C to form an oil phase. Components (1), (9), (10), (1
2) is heated and dissolved in component (13), mixed, and kept at 75°C to form an aqueous phase. Add the aqueous phase to the oil phase and emulsify and disperse the ingredients (
Add 11) and cool to 30°C while stirring to form a product.
【0023】実施例−8 パック
(1)ヤグルマソウのプロピレングリコール
抽出物(固形物として20%)
3.0部(2)ポリビニルアルコール
11.5(
3)1,3−ブチレングリコール
2.5(4)ポリオキシエチレン(4
0)
硬化ヒマシ油
1.0(5)
エチルアルコール
7.0(6)パラオキシ安息香
酸メチル 0
.2(7)香料
0.0
5(8)精製水にて全量を100とする
成分(1)から(8)を75℃にて加温溶解し、30℃
まで冷却し製品とする。Example-8 Pack (1) Cornflower propylene glycol
Extract (20% as solids)
3.0 parts (2) Polyvinyl alcohol
11.5 (
3) 1,3-butylene glycol
2.5 (4) polyoxyethylene (4
0) Hydrogenated castor oil
1.0 (5)
Ethyl alcohol
7.0(6) Methyl paraoxybenzoate 0
.. 2(7) Fragrance
0.0
5(8) Dissolve components (1) to (8) to a total volume of 100 with purified water at 75°C, and dissolve at 30°C.
Cool it until it becomes a product.
【0024】[0024]
【発明の効果】本発明のゆきのした科の植物の水溶性抽
出物を有効成分として含有する化粧料は、安定性の高い
美白作用及び抗炎症作用をあわせ持ち、かつ安全性にお
いても好ましいものである。以下、実験例を挙げて本発
明の効果を説明する。[Effects of the Invention] The cosmetic composition of the present invention containing a water-soluble extract of a plant belonging to the Yukinoshita family as an active ingredient has highly stable whitening and anti-inflammatory effects, and is also preferable in terms of safety. be. Hereinafter, the effects of the present invention will be explained by giving experimental examples.
【0025】[実験例]
有効性試験例1 美白作用
チロジナーゼ活性阻害作用を調べるため、試料の0.0
5%水溶液について37℃、2週間の保温処理をする前
後のチロジナーゼ活性阻害力を測定した。比較例として
、従来より化粧料として用いられているアスコルビン酸
、ヘチマ水およびヘチマ果実の熱水抽出物を同様に試験
した。なお、試料は実施例1で得られた抽出物を用いた
。またヘチマの熱水抽出物(比較例)の調製方法として
は、乾燥品10gを熱水抽出(95℃、3時間、300
ml)後、濾液を真空凍結乾燥した。[Experimental Example] Efficacy Test Example 1 In order to investigate the whitening effect and tyrosinase activity inhibition effect, 0.0
The tyrosinase activity inhibition power of the 5% aqueous solution was measured before and after incubation at 37°C for 2 weeks. As comparative examples, ascorbic acid, loofah water, and a hot water extract of loofah fruit, which have been conventionally used as cosmetics, were similarly tested. Note that the extract obtained in Example 1 was used as the sample. In addition, as a method for preparing a loofah hot water extract (comparative example), 10 g of the dried product was extracted with hot water (95°C, 3 hours, 300
ml), the filtrate was lyophilized in vacuo.
【0026】チロジナーゼ活性阻害作用の測定;試験管
にL−チロシン溶液(0.3mg/ml)を1ml、マ
ックスベイン氏の緩衝液(pH6.8)を1ml、およ
び前記試料の0.15%水溶液0.9mlを加えて、3
7℃の恒温水槽中で10分間インキューベートした。こ
れにチロジナーゼ水溶液(1mg/ml)を0.1ml
加えてよく攪拌し、37℃、12分間インキュベート後
、分光光度計にセットして475nmにおける吸光度を
測定した。一方、ブランクとして前記試料の代わりに蒸
留水を用いて同様の吸光度測定を行い、各試料のチロジ
ナーゼ活性阻害率を次式より算出した。なお、式中のA
は各試料を添加した場合の吸光度を、Bはブランクの吸
光度を意味する。
阻害率(%)=(1−A/B)×100Measurement of tyrosinase activity inhibition; In a test tube, add 1 ml of L-tyrosine solution (0.3 mg/ml), 1 ml of Max Bain's buffer (pH 6.8), and 0.15% aqueous solution of the above sample. Add 0.9ml, 3
It was incubated for 10 minutes in a constant temperature water bath at 7°C. Add 0.1 ml of tyrosinase aqueous solution (1 mg/ml) to this.
After stirring well and incubating at 37° C. for 12 minutes, the mixture was set in a spectrophotometer and the absorbance at 475 nm was measured. On the other hand, similar absorbance measurements were performed using distilled water instead of the sample as a blank, and the tyrosinase activity inhibition rate of each sample was calculated using the following formula. In addition, A in the formula
B means the absorbance when each sample is added, and B means the absorbance of the blank. Inhibition rate (%) = (1-A/B) x 100
【0027】こ
れらの試験結果を表1に示す。表1より明らかなように
実施例−1で得たユキノシタの水溶性抽出物は、ヘチマ
水およびヘチマの熱水抽出物よりも顕著なチロジナーゼ
活性阻害力を有しており、更にこの組成物は熱安定性が
良く、37℃、2週間放置後では、ビタミンCよりも強
力なチロジナーゼ活性阻害力を有していることが認めら
れる。また、これらの安定性試験により、ユキノシタの
水溶性抽出は変臭、変色が見られなかった。さらに実施
例2〜4で得られたゆきのした科の植物の水溶性抽出物
も同様に試験したところ、同程度に良好なチロジナーゼ
活性阻害力を示すことが判った。The results of these tests are shown in Table 1. As is clear from Table 1, the water-soluble extract of Saxifrage obtained in Example-1 has a more remarkable ability to inhibit tyrosinase activity than the loofah water and the hot water extract of loofah, and furthermore, this composition It has good thermal stability, and after being left at 37°C for 2 weeks, it was found to have a stronger inhibitory effect on tyrosinase activity than vitamin C. Furthermore, these stability tests revealed that the water-soluble extract of Saxifrage did not exhibit any odor or discoloration. Furthermore, when the water-soluble extracts of plants of the Yukinoshita family obtained in Examples 2 to 4 were similarly tested, they were found to exhibit equally good tyrosinase activity inhibition ability.
【0028】[0028]
【表1】[Table 1]
【0029】有効性試験例2 抗炎症作用抗炎症作用
を調べるため、試料を0.01%、0.1%、1.0%
含有する各水溶液について、ヒスタミン遊離抑制試験を
実施した。比較例として従来より化粧料に用いられてい
るヘチマ水およびキタチアロエの熱水抽出物を同様に試
験した。ユキノシタの水溶性抽出物、ヘチマ水は実験例
1で使用したものと同じである。またキダチアロエの熱
水抽出物(比較例)の調整方法としては、乾燥品10g
を水300mlで3時間加熱抽出し、真空凍結乾燥した
(99%以上の固形物を含む)。Efficacy test example 2 Anti-inflammatory effect In order to examine the anti-inflammatory effect, samples were mixed at 0.01%, 0.1%, and 1.0%.
A histamine release inhibition test was conducted for each aqueous solution contained. As comparative examples, loofah water and a hot water extract of Aloe albopictus, which have been conventionally used in cosmetics, were similarly tested. The water-soluble extract of Saxifrage and loofah water were the same as those used in Experimental Example 1. In addition, as a method for preparing a hot water extract (comparative example) of Kidachialoe, 10g of dried product
was heated and extracted with 300 ml of water for 3 hours, and lyophilized under vacuum (containing more than 99% solids).
【0030】ヒスタミン遊離抑制試験;平井らの報告(
生薬学雑誌、37、374,1983.)に従って、雄
性Spraque−Dawley系ラット(200から
450g)の腹腔内から採取した肥満細胞に対するヒス
タミン遊離抑制作用を測定した。すなわち、4ppmの
コンパウンド48/80によるヒスタミン遊離を抑制す
る作用を遊離抑制率(%)として求めた。Histamine release inhibition test; report by Hirai et al. (
Journal of Pharmaceutical Sciences, 37, 374, 1983. ), the inhibitory effect on histamine release on mast cells collected intraperitoneally from male Spraque-Dawley rats (200 to 450 g) was measured. That is, the effect of suppressing histamine release by 4 ppm of compound 48/80 was determined as release inhibition rate (%).
【0031】結果を表2に示す。これらの結果から、実
施例−1で得たユキノシタの熱水抽出物はヘチマ水およ
びキタチアロエの熱水抽出物と比較して、顕著なヒスタ
ミン遊離抑制作用が認められ、抗炎症作用も優れている
ことを見出した。また実施例2〜4で得られたゆきのし
た科の植物の水溶性抽出物も同様に試験したところ、良
好な抗炎症作用を示すことが判った。The results are shown in Table 2. From these results, the hot water extract of Saxifrage obtained in Example 1 was found to have a remarkable effect of inhibiting histamine release and also has excellent anti-inflammatory effect, compared to loofah water and the hot water extract of Aloe albopictus. I discovered that. Furthermore, when the water-soluble extracts of plants of the Yukinoshita family obtained in Examples 2 to 4 were similarly tested, they were found to exhibit good anti-inflammatory effects.
【0032】[0032]
【表2】[Table 2]
【0033】有効性試験例3 使用試験健康な被験者
30名を用いて使用試験を実施した。試料は実施例−5
および6の化粧料を用い、ゆきのした科の植物の水溶性
抽出物の重量%を各々変化させ用いた。被験者の前腕内
側部の2cm平方のサイトに、UV−Bランプ(東芝F
L−20SE)を用い、3mw/cm2の強度の紫外線
を1分間照射した。各サイトに先の各試料を3日間毎日
朝夕の2回塗布した後、炎症の抑制効果をアンケート調
査し評価を行った。1カ月間使用後の色素沈着の抑制効
果についてもアンケート調査を行って評価を行った。な
お、紫外線照射したうちの1サイトは何も塗布しないコ
ントロールとした。アンケートの判定基準は下記に基ず
いてコントロールと比較して評価を行った。
(判定基準)
有効 ◎
やや有効 ○ほと
んど無効 △無効
×Efficacy Test Example 3 Usage Test A usage test was conducted using 30 healthy subjects. The sample is Example-5
Cosmetics No. 6 and No. 6 were used, and the weight percent of the water-soluble extract of a plant belonging to the Yukinoshita family was varied. A UV-B lamp (Toshiba F
L-20SE) was used to irradiate ultraviolet rays with an intensity of 3 mw/cm2 for 1 minute. After each sample was applied to each site twice a day in the morning and evening for three days, the anti-inflammation effect was evaluated through a questionnaire survey. A questionnaire survey was also conducted to evaluate the pigmentation suppressing effect after one month of use. Note that one site that was irradiated with ultraviolet rays was used as a control in which nothing was applied. The evaluation criteria of the questionnaire were based on the following and compared with the control. (Judgment criteria) Valid ◎
Slightly effective ○Almost ineffective △Ineffective
×
【0034】[0034]
【表3−1】[Table 3-1]
【0035】[0035]
【表3−2】[Table 3-2]
【0036】表3の結果により本発明で用いる化粧料は
著効な日焼け後の炎症および色素沈着の抑制効果を示す
ことが判る。The results shown in Table 3 show that the cosmetics used in the present invention exhibit a remarkable effect of suppressing inflammation and pigmentation after sunburn.
【0037】有効性試験例4 安全性試験本発明のゆ
きのした科の植物の水溶性抽出物の安全性を明らかにす
るため、ヒトに対する一次刺激性試験を閉塞パッチテス
トにより行った。すなわち、フィンチャンバー(EPI
TEST社製)を用い、健康人30名に対し、前腕屈側
部に48時間閉塞貼付を行い、パッチテスト用絆創膏除
去後、1時間後、24時間後、48時間後の判定の平均
値を用いて判定した。試料は実施例−1で得られた水溶
性抽出物を用い、塗布濃度は10%(W/W)水溶液と
し、対照として蒸留水を使用した。判定結果、ユキノシ
タの水溶性抽出物では全く紅班を認めず、一方、対照の
蒸留水では5名にわずかな紅班を認めた。
これらの結果からユキノシタの水溶性抽出物は一次刺激
性が極めて低く、皮膚に対して安全が高いことが確認さ
れた。また、実施例−2〜4で得られたゆきのした科の
植物の水溶性抽出物も同様に試験し、皮膚に対して同様
に安全性が高いことが認められた。Efficacy Test Example 4 Safety Test In order to clarify the safety of the water-soluble extract of the Yukinoshita family plant of the present invention, a primary irritation test on humans was conducted by an occlusive patch test. That is, the fin chamber (EPI
(manufactured by TEST) was applied to 30 healthy people on the flexor side of their forearm for 48 hours, and after removal of the patch test bandage, the average value of the results 1 hour, 24 hours, and 48 hours later was calculated. The judgment was made using The sample used was the water-soluble extract obtained in Example-1, the coating concentration was 10% (W/W) aqueous solution, and distilled water was used as a control. As a result of the evaluation, no erythema was observed with the water-soluble extract of Saxifrage, while slight erythema was observed in 5 subjects with the control distilled water. These results confirmed that the water-soluble extract of Saxifrage has extremely low primary irritation and is highly safe for the skin. In addition, the water-soluble extracts of plants of the Yukinoshita family obtained in Examples 2 to 4 were similarly tested and found to be similarly highly safe for the skin.
Claims (1)
含有することを特徴とする化粧料。1. A cosmetic product containing a water-soluble extract of a plant belonging to the Yukinoshita family.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03271691A JP3084104B2 (en) | 1991-05-24 | 1991-05-24 | Cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP03271691A JP3084104B2 (en) | 1991-05-24 | 1991-05-24 | Cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04346911A true JPH04346911A (en) | 1992-12-02 |
JP3084104B2 JP3084104B2 (en) | 2000-09-04 |
Family
ID=17503505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03271691A Expired - Lifetime JP3084104B2 (en) | 1991-05-24 | 1991-05-24 | Cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3084104B2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0558870A (en) * | 1991-08-27 | 1993-03-09 | Suntory Ltd | Beautifying and whitening composition |
JPH05301821A (en) * | 1992-04-23 | 1993-11-16 | Kao Corp | Medicated cosmetic |
US5773014A (en) * | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
US6723667B1 (en) | 1997-04-25 | 2004-04-20 | Kanebo, Ltd. | Pack preparation |
JP2006069954A (en) * | 2004-09-01 | 2006-03-16 | Maruzen Pharmaceut Co Ltd | Tyrosinase activity inhibitor, skin whitening agent and skin cosmetic |
JP2006124355A (en) * | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | Phagocytosis inhibitor |
WO2007011148A1 (en) * | 2005-07-18 | 2007-01-25 | Korea Research Institute Of Bioscience And Biotechnology | A composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
WO2008081831A1 (en) * | 2006-12-26 | 2008-07-10 | Shiseido Company Ltd. | External preparation for skin and skin-whitening agent |
JP2011068576A (en) * | 2009-09-24 | 2011-04-07 | Pola Chemical Industries Inc | External preparation for skin whitening |
JP2011184392A (en) * | 2010-03-10 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | MELANIN PRODUCTION INHIBITOR, ENDOTHELIN-1mRNA EXPRESSION INHIBITOR, STEM CELL PROLIFERATION FACTOR (SCF) mRNA EXPRESSION INHIBITOR, BASIC FIBROBLAST GROWTH FACTOR (bFGF) mRNA EXPRESSION INHIBITOR, GLUTATHIONE PRODUCTION PROMOTER, DAMAGE INHIBITOR TO HYDROGEN PEROXIDE, AND FILAGGRIN PRODUCTION PROMOTER |
KR101449559B1 (en) * | 2012-05-18 | 2014-10-13 | 한국콜마주식회사 | Plant extract from saxifragaceae plants having skin whitening effect and skin whitening cosmetic composition containing it as active ingredient |
CN111643430A (en) * | 2020-07-22 | 2020-09-11 | 广州清淞泉生物科技有限公司 | Eye essence for treating dark eye circles by cooperation with laser and preparation method thereof |
CN111700847A (en) * | 2020-07-22 | 2020-09-25 | 广州清淞泉生物科技有限公司 | Composition for treating dark eye circles by synergistic laser, eye essence and preparation method |
-
1991
- 1991-05-24 JP JP03271691A patent/JP3084104B2/en not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0558870A (en) * | 1991-08-27 | 1993-03-09 | Suntory Ltd | Beautifying and whitening composition |
JPH05301821A (en) * | 1992-04-23 | 1993-11-16 | Kao Corp | Medicated cosmetic |
US5773014A (en) * | 1996-10-07 | 1998-06-30 | Bioetica, Inc. | Compositions and methods for inhibiting the formation of unwanted skin pigmentation |
US6723667B1 (en) | 1997-04-25 | 2004-04-20 | Kanebo, Ltd. | Pack preparation |
JP2006069954A (en) * | 2004-09-01 | 2006-03-16 | Maruzen Pharmaceut Co Ltd | Tyrosinase activity inhibitor, skin whitening agent and skin cosmetic |
JP2006124355A (en) * | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | Phagocytosis inhibitor |
WO2007011148A1 (en) * | 2005-07-18 | 2007-01-25 | Korea Research Institute Of Bioscience And Biotechnology | A composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
WO2008081831A1 (en) * | 2006-12-26 | 2008-07-10 | Shiseido Company Ltd. | External preparation for skin and skin-whitening agent |
JP2011068576A (en) * | 2009-09-24 | 2011-04-07 | Pola Chemical Industries Inc | External preparation for skin whitening |
JP2011184392A (en) * | 2010-03-10 | 2011-09-22 | Maruzen Pharmaceut Co Ltd | MELANIN PRODUCTION INHIBITOR, ENDOTHELIN-1mRNA EXPRESSION INHIBITOR, STEM CELL PROLIFERATION FACTOR (SCF) mRNA EXPRESSION INHIBITOR, BASIC FIBROBLAST GROWTH FACTOR (bFGF) mRNA EXPRESSION INHIBITOR, GLUTATHIONE PRODUCTION PROMOTER, DAMAGE INHIBITOR TO HYDROGEN PEROXIDE, AND FILAGGRIN PRODUCTION PROMOTER |
KR101449559B1 (en) * | 2012-05-18 | 2014-10-13 | 한국콜마주식회사 | Plant extract from saxifragaceae plants having skin whitening effect and skin whitening cosmetic composition containing it as active ingredient |
CN111643430A (en) * | 2020-07-22 | 2020-09-11 | 广州清淞泉生物科技有限公司 | Eye essence for treating dark eye circles by cooperation with laser and preparation method thereof |
CN111700847A (en) * | 2020-07-22 | 2020-09-25 | 广州清淞泉生物科技有限公司 | Composition for treating dark eye circles by synergistic laser, eye essence and preparation method |
CN111700847B (en) * | 2020-07-22 | 2020-12-22 | 广州杨森药业有限公司 | Composition for treating dark eye circles by synergistic laser, eye essence and preparation method |
Also Published As
Publication number | Publication date |
---|---|
JP3084104B2 (en) | 2000-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2890212B2 (en) | Cosmetics | |
JP3135943B2 (en) | Whitening agent | |
JPH04346911A (en) | Cosmetic | |
JP3415200B2 (en) | External preparation for skin | |
JP3170070B2 (en) | External preparation for skin | |
JP3817114B2 (en) | Antioxidant and external preparation for skin containing the same | |
JPH08175958A (en) | Skin agent for external use | |
JP2896815B2 (en) | Cosmetics | |
JP3010560B2 (en) | Cosmetics | |
JPH04346912A (en) | Cosmetic | |
JP5144362B2 (en) | Topical skin preparation | |
JPH01139517A (en) | Cosmetic | |
JPH04279511A (en) | Cosmetic | |
JP2896816B2 (en) | Cosmetics | |
JPH0665045A (en) | Skin external preparation | |
JPH05294819A (en) | Beautifying cosmetic | |
JP2896814B2 (en) | Cosmetics | |
JP3027409B2 (en) | Cosmetics | |
JP2002068956A (en) | Skin cosmetics | |
JP3452671B2 (en) | External preparation for skin | |
JPH04356416A (en) | Skin cosmetic | |
JP3693243B2 (en) | Whitening cosmetics | |
JP3224962B2 (en) | External preparation for skin | |
JPH0825865B2 (en) | Cosmetics for preventing skin aging | |
JPH05320034A (en) | Cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110630 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term |